Evidence map›Paper›PMID 25622201›Full record

Trial reportJournal of consulting and clinical psychology2015

Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: The significance of early rapid response.

Carlos M Grilo, Marney A White, Robin M Masheb, Ralitza Gueorguieva

Erratum issued 2 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of consulting and clinical psychology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00537810 phase4completednot on this map

Treatment of Binge Eating in Obese Patients in Primary Care

TypeinterventionalSponsorYale UniversityRan2007 to 2012Enrolled104ConditionsObesity, Binge EatingArmsSibutramine, Placebo, Self-help CBT + Sibutramine, Self-help CBT + Placebo
NCT02940613 naterminatednot on this mapstarted 2016, after this paper: background citation

Do Visuals of Symptom Change Increase Rates of Rapid Response in First Weeks of CBT for Eating Disorders?

TypeinterventionalSponsorSt. Joseph's Healthcare HamiltonRan2016 to 2020Enrolled80ConditionsBulimia Nervosa, Binge Eating DisorderArmsVisual feedback of symptom frequency
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Early Symptom Trajectories as Predictors of Treatment Outcome for Citalopram Versus Placebo.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2017
    Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Women Veterans' Treatment Preferences for Disordered Eating.Women's health issues : official publication of the Jacobs Institute of Women's Health
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Carlos M GriloDepartment of Psychiatry, Yale University School of Medicine.
Marney A WhiteDepartment of Psychiatry, Yale University School of Medicine.
Robin M MashebDepartment of Psychiatry, Yale University School of Medicine.
Ralitza GueorguievaDepartment of Biostatistics, Yale University School of Public Health.
Yale University · US

Funding

Yale University Clinical and Translational Science Award ProgramUL1TR000142 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$31.8M
Treatment of Binge Eating in Obese Patients in Primary CareR01DK073542 · NIDDK · YALE UNIVERSITY · PI GRILO, CARLOS M · 2007 to 2011
$1.7M
Mid-Career Investigator Award in Eating and WeightK24DK070052 · NIDDK · YALE UNIVERSITY · PI GRILO, CARLOS M · 2005 to 2015
$1.4M
NCATS NIH HHS UL1 TR000142NIDDK NIH HHS K24 DK070052NIDDK NIH HHS R01 DK073542
6 · The paper itself

Abstract

objectiveWe examined rapid response among obese patients with binge-eating disorder (BED) in a randomized clinical trial testing antiobesity medication and self-help cognitive-behavioral therapy (shCBT), alone and in combination, in primary-care settings.

methodOne hundred four obese patients with BED were randomly assigned to 1 of 4 treatments: sibutramine, placebo, shCBT + sibutramine, or shCBT + placebo. Treatments were delivered by generalist primary-care physicians and the medications were given double-blind. Independent assessments were performed by trained and monitored doctoral research clinicians monthly throughout treatment, posttreatment (4 months), and at 6- and 12-month follow-ups (i.e., 16 months after randomization). Rapid response, defined as ≥65% reduction in binge eating by the fourth treatment week, was used to predict outcomes.

resultsRapid response characterized 47% of patients, was unrelated to demographic and baseline clinical characteristics, and was significantly associated, prospectively, with remission from binge eating at posttreatment (51% vs. 9% for nonrapid responders), 6-month (53% vs. 23.6%), and 12-month (46.9% vs. 23.6%) follow-ups. Mixed-effects model analyses revealed that rapid response was significantly associated with greater decreases in binge-eating or eating-disorder psychopathology, depression, and percent weight loss. DISCUSSION: Our findings, based on a diverse obese patient group receiving medication and shCBT for BED in primary-care settings, indicate that patients who have a rapid response achieve good clinical outcomes through 12-month follow-ups after ending treatment. Rapid response represents a strong prognostic indicator of clinically meaningful outcomes, even in low-intensity medication and self-help interventions. Rapid response has important clinical implications for stepped-care treatment models for BED. CLINICAL

trial registrationclinicaltrials.gov: NCT00537810 (PsycINFO Database Record

Indexed as

Cognitive Behavioral TherapySelf CareAdultAnti-Obesity AgentsBinge-Eating DisorderCombined Modality TherapyCyclobutanesDouble-Blind MethodFemaleHealth BehaviorHumansMaleMiddle AgedObesityPrimary Health CarePrognosisAnti-Obesity AgentsCyclobutanessibutramine

Identifiers

PMID25622201
PMCPMC4380674
OpenAlexW2076137168

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.